




RealRate

PHARMACEUTICAL 2023

Calithera Biosciences Inc
Rank 330 of 471



The relative strengths and weaknesses of Calithera Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Calithera Biosciences Inc is the variable Net Income, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is 166%, being 78% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	26,624	Assets	28,676
Cost of Goods Sold	0	Liabilities	8,284
Intangible Assets	0	Expenses	42,074
Liabilities, Current	7,390	Revenues	0
Liabilities, Non-Current	136	Stockholders Equity	20,392
Other Assets	1,618	Net Income	-39,650
Other Compr. Net Income	0	Comprehensive Net Income	-39,650
Other Expenses	0	BaseVar	40,729
Other Liabilities	758	ECR before LimitedLiability	26%
Other Net Income	2,424	Economic Capital Ratio	166%
Other Revenues	0		
Property and Equipment	434		
Research and Development	28,533		
Selling, General and Administrative Expense	13,541		